Enveric Biosciences, Inc. Common Stock
ENVB XNAS
$1.27
-0.05 (-4.03%)
▼
15-min delayed
Open
$1.32
High
$1.33
Low
$1.27
Volume
84.8K
Market Cap
$5.40M
About Enveric Biosciences, Inc. Common Stock
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $-303 | $-1,633,473 | $-1.08 |
| FY 2025 | $-106 | $-8,771,987 | $-36.24 |
| Q3 2025 | $274 | $-1,873,669 | $-10.81 |
| Q2 2025 | $-132 | $-2,519,181 | $-0.97 |
Earnings & Analyst Ratings
Next Earnings:
Wed, Aug 12, 2026
Calendar →
TickerDaily Coverage
Stock Market Today, April 24, 2026: Microcaps Surge on Biotech Optimism
Market News
David Brooks · Apr 24, 2026
Friday, April 24, 2026 marked the end of a remarkable week for speculative growth stocks, with...
Why Is Enveric Biosciences, Inc. Common Stock (ENVB) Stock Up 61.2% Today?
Market News
Alex Chen · Apr 24, 2026
Enveric Biosciences stock exploded 61.2% to $6.71 on Friday, April 24, 2026, after President Trump...
Why Is Enveric Biosciences, Inc. Common Stock (ENVB) Stock Up 169.2% Today?
Penny Stocks
Marcus Rivera · Apr 20, 2026
Enveric Biosciences (ENVB) ripped 169.2% higher to $4.915 on Monday, crushing the previous close of...
View All Coverage →
Get ENVB Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Enveric Biosciences, Inc. Common Stock.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.